Salles et al 5 yr results of POLARIX 1L RCT PolaRCHP vs RCHOP in IPI 2-5 DLBCL 5-year PFS estimates 64.2% vs 59.1% HR 0.78; 95% CI: 0.623-0.980 5-year OS 82.2% vs 79.6% not significant #ASH2024 #lymsm

Paper in British Journal of Haematology suggests an HLA linked genetic predisposition for VITT. This is a small number of patients. Before I am convinced, I would like to see these data replicated in another cohort (of larger number of patients). tinyurl.com/bde3jcsy #VITT

Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable AmericanJournalofHematology onlinelibrary.wiley.com/doi/full/10.10…

Oral HRT increases venous thrombotic risk (VTE). Tibolone increases arterial but not VTE risk. Topical HRT showed no increase in either. Huge prospective Swedish study: 919,614 women of whom 77,512 started HRT. tinyurl.com/85jxatux #HRT

MGUS is common and can cause lots of problems. Important for all physicians to know the 5 main scenarios. #MedTwitter 1) MGUS that’s just MGUS, and nothing more. Associated with nothing else (this is by far the most common scenario). 2) MGUS that is seemingly associated with

New look PBM web content on Hospitals & Science website. Intuitive, navigable and more accessible. Thank you to all our user testers. Let us know what you think at [email protected] hospital.blood.co.uk/patient-servic…

So much change in R/R #DLBCL over recent years! See the updated BSH - Haematology guidelines now online onlinelibrary.wiley.com/doi/10.1111/bj…

🚨 Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline Full text here: buff.ly/fIxuSNz BSH - Haematology Sridhar Chaganti Bernard Maybury Chris Fox Toby Eyre Kate Cwynarski

Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national database buff.ly/gCmZUaR

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients buff.ly/ocX5Peb

BSH is proud to be once again sponsoring the 20th Annual Sickle Cell & Thalassaemia Conference hosted by the Academy for Sickle Cell & Thalassaemia #ASCAT25 You have until 9 June to submit your abstract, find out more: ow.ly/a0yU50VZRrG

O negative blood stocks are still running very low 🅾️🩸NHS Blood and Transplant are now publishing available blood donation slots on their website 👇 These slots are free today

A few friends have asked me blood donor eligibility questions, this page from NHSBT is very handy if you are unsure if you can donate blood.co.uk/who-can-give-b… 🅱️🆎🅾️🅰️🩸

🩸June issue! Studies on iptacopan for paroxysmal nocturnal haemoglobinuria, machine-learning models to predict iron recovery after blood donation & hypofractionated radiotherapy for non-Hodgkin lymphoma. Cover Series on Adverse Event Reporting! 👇 shorturl.at/a2VLi

Restrictive platelet transfusion strategies are recommended for various clinical populations to minimize adverse reactions, mitigate platelet shortages, reduce costs, and ensure patient-centric care. #ISBTMilan ISBT Central Office ja.ma/3FunxqF

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance iStopMM JAMA Oncology #mmsm jamanetwork.com/journals/jamao… Important data coming to support need for new ranges of normal free light chains based on eGFR👇

📖 Platelet disorders and treatments: a comprehensive review ⬇️ 📌 Zhang et al. review common causes of thrombocytopenia and thrombocytosis, and treatments for these two conditions Read on TH 👉 tinyurl.com/bddn7725 #Platelets #Hematology #Thrombosis

#ASCO25 Should we treat older adult with #TP53m #AML? 👇🏽 Have a look at our poster today. #COMMAND_consortium Rory M. Shallis, MD Amer Zeidan MBBS,MHS ‏عامر زيدان Anand Patel Yasmin Abaza Alexander Coltoff, MD Chenyu Lin, MD et al.

#ASCO25 #CML “best choice of frontline TKI for CML” educational session, presented by Dr. Timothy Hughes. 1. No TKI is best for every pts, choice should be individualized based on pt profile. 2. Asciminib may be a better choice for younger pt looking for TFR, except for ASXL1,

Heparin Induced Thrombocytopenia made easy! 1. Stop heparin 2. Initiate non-heparin anticoagulant (Bivalrudin, Argatroban,Fondaparinux) 4. Upper/LE US for clots 5. Add heparin to allergy list 6. Transition to DOAC when Plt>150 7. Continue DOAC 1 month (if no VTE), 3-6 if VTE